Novartis Investigative Site

Sunderland, Tyne and Wear SR4 7TP

0 studies enrolling now · 5 studies all time

What they study most

Cardiovascular Disease and Lipoprotein(a), Chronic Heart Failure With Reduced Ejection Fraction, Diabetes Mellitus and Heart Failure, Heart Failure With Preserved Ejection Fraction

Studies at this site

• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
• A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure — Stopped early
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed